首页 | 官方网站   微博 | 高级检索  
     

血必净对免疫抑制脓毒症模型的保护作用
引用本文:张晶晶,孔宪斌,霍景瑞,王蕾,刘颖,陈锋,杨晓晖,田毅,孙世中,陈旭义,黄梦强,刘英富.血必净对免疫抑制脓毒症模型的保护作用[J].天津医药,2018,46(9):932-936.
作者姓名:张晶晶  孔宪斌  霍景瑞  王蕾  刘颖  陈锋  杨晓晖  田毅  孙世中  陈旭义  黄梦强  刘英富
作者单位:1沧州医学高等专科学校科技实验中心(邮编061001);2天津中医药大学研究生院;3武警后勤学院附属医院;4天津医科大学研究生院
摘    要:目的 观察血必净对免疫抑制脓毒症小鼠的影响。方法 使用随机数字表法将152只小鼠分为对照组(Control)、免疫抑制组(IM)、免疫抑制脓毒症模型组(ISM)、血必净治疗组(XT),每组38只小鼠。IM组沿下腹正中线旁边腹腔注射环孢素A免疫抑制,25 mg/kg,隔日1次,共3次。ISM组免疫抑制后沿下腹正中线旁边腹腔注射300 μL浓度为1×109 CFU /mL的大肠杆菌44102;XT组免疫抑制脓毒症造模后30 min,沿下腹正中线旁边腹腔注射血必净4mL/kg,30 min后按相同剂量重复注射1次;Control组注射等体积的生理盐水。(1)造模8 h,各组取4只小鼠,进行血细菌培养。(2)造模12 h,各组取10只小鼠,使用流式细胞法检测外周血CD3+CD4+和CD3+CD8+。(3)造模12 h,各组取10 只小鼠,采用酶联免疫吸附试验(ELISA)检测外周血肿瘤坏死因子(TNF)-α、白细胞介素(IL)-6。(4)造模12 h,各组取4只小鼠,采用蛋白免疫印迹法测定高迁移率蛋白(HMGB1)。(5)造模12 h,各组取10只小鼠,使用全自动分析仪检测外周血丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、尿素氮(BUN)、血肌酐(CR)。结果 与ISM组相比,XT组的CD3+CD4+/CD3+CD8+的比值明显升高,血细菌培养数量明显降低;肝肾功能指标ALT、AST、CR、BUN和炎症指标TNF-α、IL-6、HMGB1均明显下降。结论 血必净能够明显调节免疫抑制脓毒症小鼠的免疫系统,对抗细菌,抑制炎症反应,并对重要器官有保护作用。

关 键 词:脓毒症  免疫抑制剂  疾病模型  动物  小鼠  近交BALB  C  血必净注射液  环孢素A  
收稿时间:2018-03-13
修稿时间:2018-05-23

The protective effect of Xuebijing on mouse model of immunosuppressed sepsis
ZHANG Jing-jing,KONG Xian-bin,HUO Jing-rui,WANG Lei,LIU Ying,CHEN Feng,YANG Xiao-hui,TIAN Yi.The protective effect of Xuebijing on mouse model of immunosuppressed sepsis[J].Tianjin Medical Journal,2018,46(9):932-936.
Authors:ZHANG Jing-jing  KONG Xian-bin  HUO Jing-rui  WANG Lei  LIU Ying  CHEN Feng  YANG Xiao-hui  TIAN Yi
Affiliation:1 Science and Technology Experiment Center of Cangzhou Medical College, Cangzhou 061001, China; 2 Graduate School of Tianjin University of Traditional Chinese Medicine; 3 the Affiliated Hospital of Logistics University of Chinese People’s Armed Police Forces; 4 Graduate School of Tianjin Medical University
Abstract:Objective To observe the effect of Xuebijing on immunosuppressed sepsis of model mice. Methods The 152 mice were randomly divided into control group (Control), immunosuppression group (IM), immunosuppressed sepsis model group (ISM) and Xuebijing treatment group (XT). There were thirty – eight mice for each group. For group IM,cyclosporine A was injected intraperitoneally along the median line of the lower abdomen for immunosuppression, 25 mg/kg,1 time every other day for a total of 3 times. For group ISM, after immunosuppression, 300 μL escherichia coli 44102 with a concentration of 1×109 CFU/mL was injected intraperitoneally along the midline of the lower abdomen. The 30 minutes after the establishment of the immunosuppressive sepsis model, Xuebijing 4 mL/kg was intraperitoneally injected along the midline of the lower abdomen in the ISM group. After 30 minutes, the same dose of Xuebijing injection was repeated once. Control group was injected intraperitoneally with the same amount of normal saline. (1) After 8 h, 4 mice in each group were taken for blood bacterial culture. (2) After 12 h, 10 mice in each group were taken for detecting CD3+CD4+ and CD3+CD8+ in peripheral blood using flow cytometry. (3) After 12 h, 10 mice in each group were taken for detecting blood levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) by enzyme-linked immunosorbent assay (ELISA). (4) After 12 h, 4 mice in each group were taken for detecting high-mobility group protein (HMGB1) by Western blot assay. (5) After 12 h, 10 mice in each group were taken for detecting alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea nitrogen(BUN) and serum creatinine (CR) levels by automatic biochemical analyzer. Results Compared with the ISM group, the ratio of CD3+CD4+/CD3+CD8+ was significantly increased, the number of blood bacteria culture decreased obviously in the XT group. Liver and kidney function indicators ALT, AST, CR, BUN and inflammatory factor indicators TNF-α, IL-6 and HMGB1 were also significantly decreased in the XT group. Conclusion Xuebijing can obviously modulate the immunosuppression, against bacteria, inhibit the inflammatory reaction, and protect the vital organs.
Keywords:Sepsis  Xuebijing injection  immunosuppressive  Cyclosporin A  
点击此处可从《天津医药》浏览原始摘要信息
点击此处可从《天津医药》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号